SLC39 (Zinc Transporter)
Zinc Transporter
SLC39 is a major zinc transporter family that affects the absorption, distribution and metabolism of zinc, controls intracellular zinc homeostasis. SLC39 transporters are encoded in human by 14 genome, which are divided into four subfamilies: subfamily I includes ZIP9 that mediates the zinc transport in the Golgi apparatus; subfamily II includes ZIP1/2/3 that transports zinc from the extracellular or organelles into the cytoplasm, regulates the zinc absorption; gufA subfamily includes ZIP11 and LIV-1 subfamily includes ZIP4/5/6/7/8/10/12/13/14 that regulate zinc absorption, transport and excretion, and are related to immune system function, inflammatory response, cadmium toxicity and iron metabolism. SLC39 dysfunction causes neurodegenerative disorders, cancer, inflammation, Ehlers-Danlos syndrome and asthma[1].
All Product Categories
-
SLC39 (Zinc Transporter) Related Products (3)
Related Products (3)
-
NVS-ZP7-4
0 ImagesNVS-ZP7-4 is an inhibitor of the zinc transporter SLC39A7 (ZIP7) and indicates ER zinc levels. ZIP7 is an active molecular node in the Notch pathway and mediates ferroptosis. NVS-ZP7-4 induces ER stress and exerts a certain ferroptosis-inhibiting effect, reduces Erastin (HY-15763)-induced cell death.
-
Anti-ZnT8 Antibody (mAb43)
0 ImagesCat. No.: HY-P992159Purity: 99.40%Anti-ZnT8 Antibody (mAb43) is a monoclonal antibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatory T cells and inhibits B cell antigen presentation, thereby effectively blocking the T cell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes.
-
Laventatug
0 ImagesCat. No.: HY-P991145CAS No.: 3009829-91-5Synonyms: BRY-812 AntibodyLaventatug (BRY-812 Antibody) is a humanized IgG1-kappa monoclonal antibody targeting hSLC39A6. Laventatug serves as the antibody component for the synthesis of the ADC molecule BRY-812 and exhibits anti-tumor activity.
